Clinical Scorecard: Laser-Titratable Shunt Shows Promise in Feasibility Study
At a Glance
| Category | Detail |
|---|---|
| Condition | Moderate to severe glaucoma |
| Key Mechanisms | Laser-titratable tube shunt with adjustable flow channels to modulate aqueous flow resistance and intraocular pressure (IOP) |
| Target Population | Patients with moderate to severe glaucoma, including those who have failed previous surgeries |
| Care Setting | Ophthalmology clinics and surgical settings |
Key Highlights
- 44.9% reduction in IOP compared to baseline
- Average postoperative IOP of 12.1 mmHg
- 88% of patients were medication-free
- Mean reduction of more than three medications per patient
- Adjustable flow channels allow for in-office pressure modifications
Guideline-Based Recommendations
Diagnosis
- Assess IOP and glaucoma severity
- Consider previous surgical history
Management
- Utilize the Calibreye system for patients with moderate to severe glaucoma
- Implement laser adjustments as needed to manage IOP
Monitoring & Follow-up
- Regular follow-up to assess IOP and medication needs
- Monitor for potential complications such as hypotony
Risks
- Potential for hypotony maculopathy
- Need for device explantation in some cases
Patient & Prescribing Data
43 patients enrolled in a feasibility study across multiple countries
Device adjustments can be made in-office to optimize IOP management
Clinical Best Practices
- Ensure proper implantation technique to minimize complications
- Utilize laser adjustments promptly to manage low IOP
- Monitor patients closely for signs of hypotony
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.